AkshaySudhindraMD

Oncology • New York, NY

Hematologic Oncology

Physician

Join to view full profile

Dr. Sudhindra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sudhindra's full profile

Already have an account?

Office
1000 10th Ave
New York, NY 10019
Phone+1 212-636-3120

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2012 - 2015
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2009 - 2012
George Washington University School of Medicine and Health SciencesClass of 2009

Certifications & Licensure

CA State Medical License 2012 - 2021
NY State Medical License 2015 - 2017
FL State Medical License Active through 2013

Clinical Trials

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab Start of enrollment: 2017 Dec 29
Completed
Phase 3
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Recruiting
Phase 3
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Start of enrollment: 2019 Feb 19
Terminated
Phase 1, Phase 2

Publications & Presentations

PubMed

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
Matthew E Stokes, Kerstin Wenzl, C Chris Huang, María Ortiz, Chih-Chao Hsu
Nature Communications. 2024-08-08
6 citations
Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
Steve Kanters, Graeme Ball, Brad Kahl, Adriana Wiesinger, Eve H Limbrick-Oldfield
BMC Cancer. 2023-01-23
6 citations
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Swetha Kambhampati, Bita Fakhri, Weiyun Z. Ai, Lawrence D. Kaplan, Joseph Tuscano
Clinical Lymphoma, Myeloma & Leukemia. 2021-03-01

Abstracts/Posters

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Akshay Sudhindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual MeetingDecember 3rd, 2018
Don't Miss Out!November 1st, 2018